nih-gov/heal.nih.gov/funding/awarded/export?combine=2R44DA043325-02&page&_format=csv

"Project #","Project Title","Research Focus Area","Research Program","Administering IC(s)",Institution(s),Investigator(s),Location(s),"Year Awarded",Summary
2R44DA043325-02,"SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE","Cross-Cutting Research","Small Business Programs",NIDA,"BreviTest Technologies, LLC","Heffernan, Michael John","HOUSTON, TX",2019,"Current drug-screening immunoassays use benchtop analyzers that require experienced personnel, time, and a laboratory setup. Physicians without access to in-house testing have to send out patient samples for screening, resulting in unacceptable delays in the treatment of patients who are potentially suffering from chronic pain. This project, a partnership with BreviTest Technologies, LLC, aims to develop a low-cost, point-of-care (POC) urine drug testing (UDT) device to detect opioids. The goal is for a portable platform to deliver quantitative performance similar to a standard laboratory test for opioids within a 10-minute run time. If successful, this will provide a technology capable of performing rapid quantifications of urine drug levels in a physician’s office, providing an invaluable tool to render more effective pain management dosing to patients, thus paving the way toward lower toxicity and a better quality of life."
		`"Project #","Project Title","Research Focus Area","Research Program","Administering IC(s)",Institution(s),Investigator(s),Location(s),"Year Awarded",Summary`
		2R44DA043325-02,"SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE","Cross-Cutting Research","Small Business Programs",NIDA,"BreviTest Technologies, LLC","Heffernan, Michael John","HOUSTON, TX",2019,"Current drug-screening immunoassays use benchtop analyzers that require experienced personnel, time, and a laboratory setup. Physicians without access to in-house testing have to send out patient samples for screening, resulting in unacceptable delays in the treatment of patients who are potentially suffering from chronic pain. This project, a partnership with BreviTest Technologies, LLC, aims to develop a low-cost, point-of-care (POC) urine drug testing (UDT) device to detect opioids. The goal is for a portable platform to deliver quantitative performance similar to a standard laboratory test for opioids within a 10-minute run time. If successful, this will provide a technology capable of performing rapid quantifications of urine drug levels in a physician’s office, providing an invaluable tool to render more effective pain management dosing to patients, thus paving the way toward lower toxicity and a better quality of life."